Compass Pathways (NASDAQ: CMPS) announced its financial results for the first quarter of 2022, which ended March 31.
Q1 Results
For the first three months of the year, net loss was $21.2 million, or $0.50 loss per share. For comparison, net loss in the same period of 2021 was $12.7 million or $0.35 loss per share.
Research and development expenses were $15.4 million, compared with $6.9 million during the same period in 2021. $5.1 million of this increase was attributable to increased external development expenses for the COMP360 psilocybin therapy in TRD. A further $2.6 million was attributable to personnel expenses, while $1.0 million was directed to non-cash, share-based compensation due to increased headcount. According to the company, this was partially offset by a decrease of $0.2 million in other expenses.
General and administrative expenses were $10.1 million, compared with $6.7 million during the same period in 2021. Regarding R&D, Compass stated that the increase is also attributable to an increase of $1 million and $0.5 million in personnel expenses and non-cash share-based compensation respectively. There was a further increase of $1.4 million in legal and professional fees and $0.4 million in facilities and other expenditures.
Company highlights
The company partnered with California-based non-profit organization One Mind to sponsor three “2022 One Mind - COMPASS Rising Stars Awards.”
On May 9, Compass announced that it intends to undertake a study, named Psilaut, to evaluate psilocybin’s effects on autistic adults. The study will be co-sponsored by the Institute of Psychiatry, Psychology & Neuroscience at King’s College London and the South London and Maudsley NHS Foundation Trust.
Also with those two organizations, Compass launched the Centre for Mental Health Research and Innovation earlier this year with the goal of researching emerging psychedelic therapies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!